Clinical trials: Operable Esophageal Cancer
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
- Trial name
- NCT03987815
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Esophageal Cancer, Gastric Cancer
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033657
- Testing
- cisplatin, irinotecan hydrochloride, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eastern Cooperative Oncology Group
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ)…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Trial name
- ZODIAC (NCT06250036)
- Testing
- Single agent zimberelimab, Combination zimberelimab + domvanalimab
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or
Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy
Step 1: Inclusion of eligible patients to carry out a translational search for prognostic and predictive markers of Complete Clinical Response and Pathologic Complete Response (using blood samples and diagnostic biopsies) and to…
- Conditions
- Epidermoid Carcinoma or, Adenocarcinoma of the Thoracic Oesophagus or, Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II), Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0
- Trial name
- Esostrate (NCT02551458)
- Testing
- Systematic surgery, Surveillance and rescue surgery in cases of resectable loco-regional recurrence
- Where
- 18 sites in France
- Volunteers
- 188 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Operable Esophageal Cancer, Embolization of the Left Gastric Artery Prior to Surgery
Gastric Ischemic Preconditioning Before Esophagectomy
The aim of the study is to investigate the impact of left gastric artery embolization before esophagectomy on postoperative complications, particularly anastomotic leaks and necrosis of the gastric conduit.
- Trial name
- NCT06453031
- Testing
- Gastric Ischemic Preconditioning Before Esophagectomy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- CHU Rennes - Hopital Pontchaillou
Esophageal Cancer
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00493025
- Testing
- cisplatin, gefitinib, paclitaxel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Cancer
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544362
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 13 sites in France
- Volunteers
- 33 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Cancer
Positron Emission Tomography in Determining Stage of Esophageal Cancer
RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer.
- Trial name
- NCT00004867
- Testing
- conventional surgery, positron emission tomography, radionuclide imaging
- Where
- 35 sites in United States
- Volunteers
- 235 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastro-esophageal Cancer
PeRioperative Study of Exercise Training in Patients With Operable Cancer of the Gastroesophageal Junction
Background: For patients diagnosed with operable cancer of the gastro-esophageal junction (GEJ), the perioperative course of therapy is associated with severe deconditioning which includes weight loss and poor physical function…
- Trial name
- PRESET (NCT02722785)
- Testing
- Aerobic and Resistance Exercise Training
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Jesper Frank Christensen, PhD
Esophageal Cancer
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551759
- Testing
- 5-Fluorouracil, Oxaliplatin, Cetuximab
- Where
- 109 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Oesophageal Cancer
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have resectable disease at diagnosis.
- Trial name
- NeoSCOPE (NCT01843829)
- Testing
- Oxaliplatin, Capecitabine, Carboplatin
- Where
- 12 sites in United Kingdom
- Volunteers
- 85 people
- Sponsor
- Lisette Nixon
Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
This multicentre, open-label, randomized phase II trial is ongoing in 30 centres in France. Main eligibility criteria include: histologically proven adenocarcinoma of the stomach, esophagus or gastroesophageal junction; locally…
- Trial name
- MEGA (NCT01443065)
- Testing
- Oxaliplatin, Folinic Acid, 5-fluoro-uracil
- Where
- France
- Volunteers
- 162 people
- Sponsor
- UNICANCER
Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer
Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer
Perioperative chemotherapy (CHT) or CHT/RT combined with surgery is the standard therapeutic approach for the treatment of locally advanced cancer of the esophagus, gastroesophageal junction (GEJ), and stomach.
- Conditions
- Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, Gastric Cancer
- Trial name
- OESOFIT (NCT07671625)
- Testing
- Cardiorespiratory fitness (FsPS), Exercises you can do on your own at home, Enhanced Recovery After Surgery ERAS
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
Esophageal Neoplasm
Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer
This study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy following photodynamic therapy have on esophageal cancer.
- Trial name
- NCT01035437
- Testing
- HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
- Sponsor
- Roswell Park Cancer Institute
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Oesophagogastric Cancer
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ST03 (NCT00450203)
- Testing
- bevacizumab, capecitabine, cisplatin
- Where
- 41 sites in United Kingdom
- Volunteers
- 1,103 people
- Sponsor
- Professor David Cunningham
Gastric Adenocarcinoma, Oesophageal Adenocarcinoma
Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
A single centre phase II trial of peri-operative chemo-immunotherapy in operable gastro-oesophageal adenocarcinoma (GOA). This trial is designed to evaluate the safety and efficacy of administering Avelumab, an anti-PD-L1…
- Trial name
- ICONIC (NCT03399071)
- Testing
- FLOT-A
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer, Esophageal Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer…
- Conditions
- Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
- Trial name
- NCT03044613
- Testing
- Nivolumab, Relatlimab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Squamous Cell Carcinoma
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of sintilimab combined with concurrent chemotherapy as a neoadjuvant treatment for patients with operable esophageal squamous cell carcinoma.
- Trial name
- NCT05174325
- Testing
- Sintilimab + chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University